Vikas Lifecare Eyes ₹99 Crore from Warrants, Plans Share Capital Boost

Vikas Lifecare Limited has submitted proposals to its shareholders for approval, aiming to raise approximately ₹99.05 crore through a preferential issue of warrants and to increase its authorized share capital.

Key Proposals for Shareholder Vote

The company is seeking shareholder consent to issue 61,90,62,500 fully convertible warrants on a preferential basis, with each warrant priced at ₹1.60, targeting a total fundraise of ₹99.05 crore. Concurrently, Vikas Lifecare proposes to raise its authorized share capital from ₹235 crore to ₹300 crore. Shareholder voting on these resolutions will take place via e-voting from April 16, 2026, to May 15, 2026.

Strategic Importance of the Capital Raise

This planned capital infusion is intended to bolster Vikas Lifecare's working capital and cover general corporate expenses. Securing these funds is crucial for enhancing the company's day-to-day operational liquidity and supporting its ongoing business activities. The increase in authorized share capital is a prerequisite for the future allotment of shares should the warrants be converted.

Company Background and Financial Context

Established in 1995 and previously known as Vikas Multicorp, Vikas Lifecare operates diversified business segments, including polymers, chemicals, agro products, and smart metering via its subsidiary Genesis Gas Solutions. The company has previously utilized preferential warrant issues for capital raising, with similar approvals secured in June 2024 and September 2023. However, Vikas Lifecare has faced financial challenges, reporting consolidated net losses, including ₹2.82 crore in Q1 FY25. It is also grappling with a slower cash cycle and declining interest coverage ratios.

Impact of Shareholder Approval

If approved by shareholders, the company will gain potential access to ₹99.05 crore for working capital and general corporate purposes. The authorized share capital will be increased to ₹300 crore, allowing for future share issuances. It is important for shareholders to note that warrants carry an inherent risk of future share dilution upon their conversion into equity.

Key Risks and Regulatory Factors

Vikas Lifecare faces several potential hurdles. The successful completion of the preferential issue requires approvals from stock exchanges and other regulatory bodies. The company also received a significant ₹22.99 crore income tax demand order on March 27, 2026. In February 2025, SEBI penalized the company ₹200,000 for alleged non-disclosure, though SEBI cleared it in a separate matter later. Furthermore, warrants typically have an 18-month validity period from allotment, after which they lapse and any invested funds are forfeited if not exercised.

Industry Peers

The company operates within sectors that include companies like Supreme Industries Ltd., a major player in plastic products; Time Technoplast Ltd., also active in plastic products manufacturing and trading; and Xpro India Ltd., a manufacturer of polymer compounds and masterbatches.

Next Steps for Investors

Investors will be closely watching the outcome of the shareholder voting on the proposed warrant issue and capital hike. Following the vote, the company will need to secure necessary approvals from stock exchanges and regulators. The subsequent allotment of warrants and the eventual deployment of the raised funds for working capital and general corporate purposes will be key areas to monitor.